Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Laurie Gaspar

Concepts (490)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
100
2022
1170
6.560
 Why?
Lung Neoplasms
91
2023
2344
5.390
 Why?
Carcinoma, Non-Small-Cell Lung
54
2022
1052
4.260
 Why?
Radiosurgery
44
2022
321
4.120
 Why?
Cranial Irradiation
20
2022
68
2.800
 Why?
Small Cell Lung Carcinoma
11
2023
89
2.680
 Why?
Combined Modality Therapy
62
2022
1204
1.280
 Why?
Radiation Pneumonitis
5
2021
28
1.250
 Why?
Radiotherapy, Intensity-Modulated
9
2018
129
1.220
 Why?
Antineoplastic Combined Chemotherapy Protocols
30
2023
1565
1.190
 Why?
Practice Guidelines as Topic
13
2021
1494
1.150
 Why?
Carcinoma, Small Cell
8
2007
169
1.150
 Why?
Neoplasm Staging
39
2020
1292
1.110
 Why?
Radiotherapy Dosage
39
2023
251
1.060
 Why?
Chemoradiotherapy
8
2020
210
1.030
 Why?
Brachytherapy
12
2017
104
0.960
 Why?
Radiotherapy Planning, Computer-Assisted
11
2021
124
0.910
 Why?
Neoplasm Recurrence, Local
21
2017
960
0.910
 Why?
Radiation Oncology
12
2022
75
0.880
 Why?
Glioblastoma
18
2016
326
0.880
 Why?
Liver Neoplasms
8
2009
640
0.770
 Why?
Glioma
15
2015
354
0.760
 Why?
Adenocarcinoma
13
2022
896
0.750
 Why?
Aged
102
2020
22052
0.740
 Why?
Esophageal Neoplasms
9
2008
293
0.720
 Why?
Survival Rate
31
2018
1874
0.710
 Why?
Humans
221
2023
129385
0.710
 Why?
Prognosis
45
2022
3791
0.710
 Why?
Middle Aged
118
2020
31102
0.680
 Why?
Radiotherapy, Conformal
8
2017
70
0.680
 Why?
Clinical Trials as Topic
18
2018
1004
0.660
 Why?
Radiotherapy
14
2017
187
0.660
 Why?
Radiotherapy, Adjuvant
16
2022
210
0.650
 Why?
Neurosurgeons
1
2019
17
0.630
 Why?
Dacarbazine
9
2016
94
0.630
 Why?
Evidence-Based Medicine
10
2021
715
0.610
 Why?
Four-Dimensional Computed Tomography
6
2021
29
0.600
 Why?
Oncologists
1
2018
35
0.560
 Why?
Patient Selection
10
2019
662
0.560
 Why?
Clinical Decision-Making
3
2021
302
0.540
 Why?
Aged, 80 and over
45
2020
7069
0.540
 Why?
Male
128
2022
63597
0.540
 Why?
Carcinoma, Squamous Cell
10
2017
623
0.540
 Why?
Cisplatin
18
2021
300
0.520
 Why?
Female
131
2020
68693
0.520
 Why?
Physician's Role
1
2018
206
0.510
 Why?
Antineoplastic Agents, Alkylating
8
2016
69
0.500
 Why?
Antineoplastic Agents
20
2017
2061
0.500
 Why?
Induction Chemotherapy
2
2013
70
0.470
 Why?
Adult
90
2020
35514
0.460
 Why?
Receptor Protein-Tyrosine Kinases
5
2017
231
0.430
 Why?
Survival Analysis
24
2020
1272
0.430
 Why?
Treatment Outcome
36
2021
10195
0.430
 Why?
Physician-Patient Relations
1
2018
537
0.410
 Why?
Etoposide
12
2021
148
0.400
 Why?
Pro-Opiomelanocortin
7
1989
17
0.380
 Why?
Pneumonectomy
2
2015
151
0.370
 Why?
Retrospective Studies
40
2022
14498
0.370
 Why?
Astrocytoma
9
2014
122
0.360
 Why?
Societies, Medical
7
2021
747
0.330
 Why?
Protein Kinase Inhibitors
4
2021
891
0.330
 Why?
Melanoma
5
2018
729
0.330
 Why?
Whole-Body Irradiation
1
2009
76
0.320
 Why?
Pulmonary Ventilation
4
2021
77
0.320
 Why?
Guidelines as Topic
2
2020
263
0.320
 Why?
Chemotherapy, Adjuvant
12
2017
381
0.320
 Why?
Medical Oncology
7
2021
272
0.320
 Why?
Guideline Adherence
4
2018
525
0.320
 Why?
Karnofsky Performance Status
11
2020
38
0.310
 Why?
ErbB Receptors
8
2022
607
0.310
 Why?
Quinazolines
6
2014
244
0.300
 Why?
Lung
9
2021
3919
0.300
 Why?
Breast Neoplasms
9
2020
2142
0.300
 Why?
Dose-Response Relationship, Radiation
11
2019
132
0.300
 Why?
Iodine Radioisotopes
6
2006
142
0.290
 Why?
Re-Irradiation
2
2018
8
0.290
 Why?
Controlled Clinical Trials as Topic
1
2007
27
0.280
 Why?
Radiopharmaceuticals
5
2014
168
0.280
 Why?
Neoplasm Metastasis
8
2019
610
0.280
 Why?
Disease Progression
13
2018
2626
0.280
 Why?
Follow-Up Studies
22
2018
4888
0.280
 Why?
Anticonvulsants
2
2019
209
0.270
 Why?
Tumor Burden
9
2017
286
0.260
 Why?
Biomarkers, Tumor
6
2021
1181
0.260
 Why?
Tomography, X-Ray Computed
10
2018
2528
0.250
 Why?
Paclitaxel
5
2011
217
0.250
 Why?
Prospective Studies
22
2018
7111
0.250
 Why?
Proto-Oncogene Proteins B-raf
2
2017
212
0.240
 Why?
Spinal Cord
4
2018
356
0.240
 Why?
Carcinoma, Hepatocellular
2
2005
272
0.230
 Why?
Steroids
2
2019
158
0.220
 Why?
Taxoids
5
2015
98
0.220
 Why?
Carcinoma
1
2006
216
0.220
 Why?
Central Nervous System
2
2017
257
0.220
 Why?
Lymphatic Metastasis
3
2017
319
0.220
 Why?
Magnetic Resonance Imaging
9
2019
3398
0.220
 Why?
Carcinoma, Renal Cell
3
2018
180
0.210
 Why?
Gastrointestinal Neoplasms
3
2019
72
0.210
 Why?
Randomized Controlled Trials as Topic
7
2021
1360
0.200
 Why?
Radiography
8
2014
798
0.200
 Why?
Necrosis
3
2019
232
0.190
 Why?
Positron Emission Tomography Computed Tomography
2
2020
85
0.190
 Why?
Medical Illustration
2
2012
9
0.190
 Why?
Organs at Risk
2
2012
31
0.190
 Why?
Ribs
2
2012
33
0.190
 Why?
Brachial Plexus
2
2012
28
0.190
 Why?
Neoplasms
6
2020
2469
0.180
 Why?
Professional Staff Committees
4
2001
13
0.180
 Why?
Oligodendroglioma
4
2014
15
0.180
 Why?
Esophagectomy
1
2002
124
0.170
 Why?
Testicular Neoplasms
1
2022
104
0.170
 Why?
Mutation
4
2021
3717
0.170
 Why?
Proportional Hazards Models
8
2020
1201
0.170
 Why?
Research Design
7
2018
1038
0.170
 Why?
Peptide Fragments
4
1989
692
0.170
 Why?
Thymus Neoplasms
2
2017
22
0.160
 Why?
Thymoma
2
2017
33
0.160
 Why?
Time Factors
10
2019
6550
0.160
 Why?
Consolidation Chemotherapy
1
2019
9
0.160
 Why?
Esophagus
2
2012
248
0.160
 Why?
Metalloporphyrins
3
2011
101
0.160
 Why?
Maximum Tolerated Dose
6
2010
193
0.160
 Why?
Radiation Injuries
5
2015
135
0.160
 Why?
Congresses as Topic
2
2019
214
0.160
 Why?
Meningeal Neoplasms
3
2017
93
0.160
 Why?
Watchful Waiting
1
2019
66
0.160
 Why?
Expert Testimony
1
2019
36
0.150
 Why?
Aquaporin 4
1
2019
95
0.150
 Why?
Gray Matter
1
2019
81
0.150
 Why?
CTLA-4 Antigen
1
2018
87
0.150
 Why?
Spinal Neoplasms
1
2018
29
0.140
 Why?
Cognition
4
2013
1120
0.140
 Why?
Intracranial Arteriovenous Malformations
2
1995
51
0.140
 Why?
Carboplatin
4
2011
140
0.140
 Why?
Intersectoral Collaboration
1
2018
60
0.140
 Why?
Kidney Neoplasms
3
2018
350
0.140
 Why?
Endpoint Determination
1
2018
76
0.140
 Why?
Receptor, ErbB-2
5
2020
326
0.140
 Why?
Quality of Life
5
2013
2695
0.140
 Why?
Treatment Failure
5
2014
339
0.140
 Why?
Professional Competence
1
2018
94
0.140
 Why?
Genes, ras
1
2017
97
0.140
 Why?
Triazines
2
2009
38
0.130
 Why?
Pituitary Neoplasms
5
1994
184
0.130
 Why?
Mortality
1
2019
307
0.130
 Why?
Decision Trees
1
1997
90
0.130
 Why?
Antineoplastic Agents, Immunological
1
2019
181
0.130
 Why?
Proto-Oncogene Proteins c-kit
1
2017
68
0.130
 Why?
Interdisciplinary Communication
1
2018
186
0.130
 Why?
Brain
5
2019
2679
0.130
 Why?
Fluorouracil
6
2004
199
0.130
 Why?
Salvage Therapy
4
2017
134
0.130
 Why?
Cohort Studies
7
2019
5414
0.130
 Why?
Hemangioma, Cavernous
2
1993
13
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2018
232
0.130
 Why?
Antibodies
1
2018
398
0.130
 Why?
Pulmonary Atelectasis
1
2015
13
0.130
 Why?
Age Factors
8
2017
3144
0.130
 Why?
Accreditation
2
2013
80
0.120
 Why?
Patient Preference
1
2018
185
0.120
 Why?
Adrenal Cortex Hormones
1
2019
520
0.120
 Why?
Radiation-Sensitizing Agents
5
2009
40
0.120
 Why?
United States
13
2022
13876
0.120
 Why?
Postoperative Care
1
2017
238
0.120
 Why?
Medically Underserved Area
1
2016
84
0.120
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2015
99
0.120
 Why?
Antineoplastic Agents, Phytogenic
2
2006
187
0.120
 Why?
Central Nervous System Neoplasms
1
2017
149
0.120
 Why?
Risk Assessment
3
2021
3236
0.110
 Why?
Carmustine
7
2010
50
0.110
 Why?
Perfusion Imaging
1
2014
56
0.110
 Why?
Fibrosarcoma
1
1993
20
0.110
 Why?
Analysis of Variance
5
2014
1287
0.110
 Why?
Camptothecin
2
2011
109
0.110
 Why?
Triple Negative Breast Neoplasms
1
2017
197
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
19
0.110
 Why?
Cerebellar Neoplasms
2
1996
156
0.110
 Why?
Adolescent
22
2017
20378
0.110
 Why?
Receptors, Progesterone
4
2020
343
0.110
 Why?
Contraindications
2
2008
90
0.110
 Why?
Nelson Syndrome
4
1987
4
0.110
 Why?
Pyrazoles
2
2014
405
0.110
 Why?
Medulloblastoma
2
1996
198
0.110
 Why?
Kaplan-Meier Estimate
5
2019
857
0.100
 Why?
Disease-Free Survival
6
2014
647
0.100
 Why?
Pyridines
2
2014
478
0.100
 Why?
Respiratory Function Tests
1
2015
585
0.100
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1356
0.100
 Why?
beta-Endorphin
3
1989
8
0.100
 Why?
Pancreatic Neoplasms
1
2000
881
0.100
 Why?
Radiotherapy, High-Energy
4
2000
13
0.090
 Why?
Particle Accelerators
1
1991
10
0.090
 Why?
Adrenocorticotropic Hormone
3
1989
133
0.090
 Why?
Bone Neoplasms
3
2007
231
0.090
 Why?
Radiation Protection
2
2009
36
0.090
 Why?
Quality Assurance, Health Care
3
2009
317
0.090
 Why?
Forced Expiratory Volume
2
2015
511
0.090
 Why?
Young Adult
8
2017
12416
0.090
 Why?
Hyperthermia, Induced
1
1992
109
0.090
 Why?
Databases, Factual
5
2017
1269
0.080
 Why?
Technology, Radiologic
1
2010
6
0.080
 Why?
Radiotherapy, Computer-Assisted
1
2010
12
0.080
 Why?
Bevacizumab
3
2015
129
0.080
 Why?
MEDLINE
1
2009
20
0.080
 Why?
Spine
1
1991
158
0.080
 Why?
Clinical Trials, Phase II as Topic
2
2002
72
0.080
 Why?
Adenoma
4
1994
213
0.080
 Why?
Severity of Illness Index
2
2008
2737
0.080
 Why?
Multivariate Analysis
6
2020
1501
0.080
 Why?
Neurosurgery
1
2009
37
0.080
 Why?
Risk Factors
7
2021
9752
0.080
 Why?
Adrenal Medulla
1
1989
7
0.080
 Why?
Palliative Care
5
2018
720
0.080
 Why?
Neurotensin
1
1989
12
0.080
 Why?
Drug Therapy
1
2009
78
0.080
 Why?
Education, Medical, Graduate
1
2013
437
0.080
 Why?
Catheter Ablation
1
2012
334
0.080
 Why?
Fractures, Spontaneous
1
1988
11
0.080
 Why?
Meta-Analysis as Topic
1
2009
169
0.080
 Why?
Piperidines
1
2010
196
0.080
 Why?
Ependymoma
2
2009
177
0.080
 Why?
Imaging, Three-Dimensional
2
2010
530
0.080
 Why?
Esophageal Fistula
2
2000
18
0.080
 Why?
Liver
2
2008
1839
0.080
 Why?
Equipment Failure Analysis
1
2009
131
0.070
 Why?
Radionuclide Imaging
1
2008
123
0.070
 Why?
Pheochromocytoma
1
1989
57
0.070
 Why?
Respiratory Mechanics
1
2008
64
0.070
 Why?
Humeral Fractures
1
1988
48
0.070
 Why?
Femoral Fractures
1
1988
73
0.070
 Why?
Positron-Emission Tomography
2
2008
286
0.070
 Why?
Adrenal Gland Neoplasms
1
1989
84
0.070
 Why?
Lymph Node Excision
1
2009
164
0.070
 Why?
Surveys and Questionnaires
2
2018
5390
0.070
 Why?
Craniopharyngioma
1
2009
82
0.070
 Why?
Chromatography, Gel
4
1989
127
0.070
 Why?
Kidney
2
2005
1384
0.070
 Why?
Pulmonary Disease, Chronic Obstructive
1
2015
982
0.070
 Why?
Statistics, Nonparametric
2
2018
422
0.070
 Why?
Radioimmunoassay
4
1989
175
0.070
 Why?
Uterine Cervical Neoplasms
1
1989
233
0.070
 Why?
Biomedical Research
2
2009
637
0.060
 Why?
Seizures
1
2009
402
0.060
 Why?
Clinical Competence
1
2013
1012
0.060
 Why?
Vascular Diseases
1
2009
241
0.060
 Why?
Whole Body Imaging
1
2006
20
0.060
 Why?
Genetic Markers
2
2017
338
0.060
 Why?
Neoplasm Grading
2
2020
285
0.060
 Why?
Hepatitis B, Chronic
1
2005
18
0.060
 Why?
Linear Models
3
2017
819
0.060
 Why?
Drug Administration Schedule
3
2014
768
0.060
 Why?
Strontium Radioisotopes
2
2006
3
0.060
 Why?
Vascular Endothelial Growth Factor A
1
2008
529
0.060
 Why?
Databases as Topic
1
2005
59
0.060
 Why?
Diagnostic Imaging
3
2009
334
0.060
 Why?
Hemoglobins
1
2007
339
0.060
 Why?
Immunotherapy
2
2022
592
0.060
 Why?
Antiemetics
1
2005
40
0.060
 Why?
Peptides
3
1985
925
0.060
 Why?
Gene Rearrangement
2
2018
148
0.060
 Why?
Delivery of Health Care
1
2012
893
0.060
 Why?
Anticoagulants
1
2009
636
0.060
 Why?
Pituitary Hormones
1
1984
16
0.060
 Why?
Organ Size
1
2005
447
0.060
 Why?
Physicians
1
2013
864
0.060
 Why?
Body Fluids
1
1985
62
0.060
 Why?
Retreatment
3
2012
69
0.060
 Why?
Practice Patterns, Physicians'
1
2013
1265
0.060
 Why?
Cognition Disorders
2
2010
504
0.060
 Why?
Age Distribution
1
2005
372
0.060
 Why?
Dexamethasone
3
2012
346
0.060
 Why?
Consensus
2
2021
613
0.060
 Why?
Sex Distribution
1
2005
359
0.060
 Why?
Feasibility Studies
3
2011
865
0.060
 Why?
Regression Analysis
2
2017
993
0.050
 Why?
Erlotinib Hydrochloride
2
2014
70
0.050
 Why?
Hepatitis C, Chronic
1
2005
153
0.050
 Why?
Internship and Residency
1
2013
1050
0.050
 Why?
Liver Cirrhosis
1
2005
280
0.050
 Why?
Preoperative Care
1
2005
337
0.050
 Why?
Propionates
1
2003
37
0.050
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
253
0.050
 Why?
Chromatography, Affinity
3
1989
83
0.050
 Why?
Aniline Compounds
1
2003
98
0.050
 Why?
Societies
1
2022
36
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2004
93
0.050
 Why?
Pterygium
1
2000
4
0.040
 Why?
Algorithms
2
2017
1620
0.040
 Why?
Organizational Objectives
4
2001
73
0.040
 Why?
Esophagoscopy
1
2002
195
0.040
 Why?
Reproducibility of Results
2
2015
3079
0.040
 Why?
Ontario
2
2017
90
0.040
 Why?
Neurologic Examination
1
2000
115
0.040
 Why?
Vincristine
2
2010
109
0.040
 Why?
B7-H1 Antigen
1
2022
196
0.040
 Why?
BRCA1 Protein
1
2020
65
0.040
 Why?
Carcinoma, Bronchogenic
1
1999
19
0.040
 Why?
Spinal Cord Neoplasms
1
1999
40
0.040
 Why?
Neuropsychological Tests
3
2013
1012
0.040
 Why?
Carcinoma, Large Cell
1
1999
15
0.040
 Why?
Receptors, Estrogen
2
2013
426
0.040
 Why?
Medical Records
2
2010
171
0.040
 Why?
Reoperation
2
2012
544
0.040
 Why?
Liver Transplantation
1
2005
831
0.040
 Why?
Urinary Bladder Neoplasms
1
2001
228
0.040
 Why?
Estrogens
1
2020
346
0.040
 Why?
Child, Preschool
7
2009
10516
0.040
 Why?
Thoracic Vertebrae
1
2018
74
0.040
 Why?
Iridium Radioisotopes
1
1997
4
0.030
 Why?
Colorado
3
2014
4415
0.030
 Why?
Epidemiologic Methods
1
2017
74
0.030
 Why?
Aziridines
2
1994
5
0.030
 Why?
Clinical Trials, Phase I as Topic
1
1997
50
0.030
 Why?
Biopsy, Needle
1
2017
189
0.030
 Why?
Molecular Weight
2
1989
331
0.030
 Why?
Precision Medicine
1
2020
387
0.030
 Why?
Skin Neoplasms
2
2017
823
0.030
 Why?
Memory Disorders
2
2010
168
0.030
 Why?
Esophagitis
2
2009
67
0.030
 Why?
Benzoquinones
2
1994
48
0.030
 Why?
Propensity Score
1
2018
265
0.030
 Why?
Respiration
1
2017
191
0.030
 Why?
Neutropenia
2
2009
134
0.030
 Why?
Supratentorial Neoplasms
1
1996
19
0.030
 Why?
Odds Ratio
1
1999
1023
0.030
 Why?
Heart
1
2020
637
0.030
 Why?
Meningioma
1
1997
81
0.030
 Why?
Estrogen Receptor alpha
1
2017
133
0.030
 Why?
Sex Factors
2
2014
1966
0.030
 Why?
Pilot Projects
3
2015
1587
0.030
 Why?
Cerebral Angiography
1
1995
109
0.030
 Why?
Forecasting
3
2001
358
0.030
 Why?
Marital Status
1
2014
44
0.030
 Why?
Myocardium
1
2020
980
0.030
 Why?
Technetium Tc 99m Pentetate
1
2014
7
0.030
 Why?
Nuclear Medicine
1
2014
7
0.030
 Why?
Ventilation-Perfusion Ratio
1
2014
10
0.030
 Why?
Patient Safety
1
2017
286
0.030
 Why?
Vital Capacity
1
2015
291
0.030
 Why?
Nervous System Diseases
1
1997
252
0.030
 Why?
Texas
1
2014
227
0.030
 Why?
Molecular Targeted Therapy
1
2017
390
0.030
 Why?
Child
9
2009
20868
0.030
 Why?
Radioisotope Teletherapy
1
1993
2
0.030
 Why?
Cobalt Radioisotopes
1
1993
7
0.030
 Why?
SEER Program
1
2014
206
0.030
 Why?
Developing Countries
1
2016
287
0.030
 Why?
Spatial Analysis
1
2013
21
0.030
 Why?
Radiodermatitis
1
1993
8
0.030
 Why?
Vimentin
1
1993
51
0.030
 Why?
Radiometry
1
2013
47
0.030
 Why?
Observer Variation
1
2014
314
0.030
 Why?
Monte Carlo Method
1
2013
143
0.030
 Why?
Scalp
1
1993
34
0.030
 Why?
Prostatic Neoplasms
1
2001
1016
0.030
 Why?
Cerebral Cortex
1
1996
436
0.030
 Why?
Time
1
2013
75
0.030
 Why?
Protein-Tyrosine Kinases
1
2016
432
0.030
 Why?
Mitosis
1
1993
180
0.030
 Why?
Ascorbic Acid
1
1993
120
0.020
 Why?
Medical Errors
1
2013
104
0.020
 Why?
Radiation Dosage
1
2013
153
0.020
 Why?
Remission Induction
2
2008
272
0.020
 Why?
Radiology
1
2014
161
0.020
 Why?
Disease Management
1
2016
586
0.020
 Why?
International Agencies
1
2011
29
0.020
 Why?
Diagnosis, Differential
1
2015
1428
0.020
 Why?
Breast Neoplasms, Male
1
2011
29
0.020
 Why?
Electrons
1
1991
79
0.020
 Why?
Bronchography
1
2010
10
0.020
 Why?
Longitudinal Studies
1
2018
2714
0.020
 Why?
Sensitivity and Specificity
1
2015
1835
0.020
 Why?
Infusions, Intravenous
2
2004
398
0.020
 Why?
Fibrosis
1
2013
520
0.020
 Why?
Cell Nucleus
1
1993
582
0.020
 Why?
Procarbazine
1
1990
8
0.020
 Why?
Lomustine
1
1990
14
0.020
 Why?
Physics
1
2010
17
0.020
 Why?
Chromatin
1
1993
479
0.020
 Why?
Neoplasm, Residual
1
2010
120
0.020
 Why?
Selection Bias
1
2009
37
0.020
 Why?
Clinical Trials Data Monitoring Committees
1
2009
6
0.020
 Why?
Hypophysectomy
1
1989
15
0.020
 Why?
Smoking
1
2017
1501
0.020
 Why?
Quality Control
1
2010
163
0.020
 Why?
Incidence
1
2016
2641
0.020
 Why?
Prevalence
1
2016
2560
0.020
 Why?
Platinum
1
2009
44
0.020
 Why?
Immunohistochemistry
1
1993
1698
0.020
 Why?
Certification
1
2010
94
0.020
 Why?
Adrenal Cortex
1
1989
27
0.020
 Why?
Bronchi
1
2010
247
0.020
 Why?
Neoplasms, Unknown Primary
1
1988
13
0.020
 Why?
Hepatic Veno-Occlusive Disease
1
2008
14
0.020
 Why?
Prostheses and Implants
1
2010
132
0.020
 Why?
Liver Regeneration
1
2008
40
0.020
 Why?
beta-Lipotropin
2
1985
2
0.020
 Why?
Endorphins
2
1985
8
0.020
 Why?
Polymorphism, Single Nucleotide
1
2016
2071
0.020
 Why?
Epinephrine
1
1989
141
0.020
 Why?
Anti-Inflammatory Agents
1
2012
480
0.020
 Why?
Administration, Oral
1
2010
785
0.020
 Why?
Motion
1
2008
98
0.020
 Why?
International Cooperation
1
2008
173
0.020
 Why?
Infant
4
1999
9023
0.020
 Why?
Mental Status Schedule
1
2007
34
0.020
 Why?
Fracture Fixation, Intramedullary
1
1988
60
0.020
 Why?
Reference Values
1
1989
793
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2281
0.020
 Why?
Rectal Neoplasms
1
2008
136
0.020
 Why?
Bleomycin
1
2009
244
0.020
 Why?
Creatinine
1
1989
490
0.020
 Why?
Predictive Value of Tests
2
2008
1945
0.020
 Why?
Chromatography, High Pressure Liquid
1
1989
582
0.020
 Why?
California
1
2008
401
0.020
 Why?
Southwestern United States
1
2006
91
0.020
 Why?
DNA Repair
1
2008
207
0.020
 Why?
Chromium Compounds
1
2006
2
0.020
 Why?
Sodium Iodide
1
2006
3
0.020
 Why?
Neovascularization, Pathologic
1
2008
297
0.020
 Why?
Methadone
1
1987
92
0.020
 Why?
Polycythemia Vera
1
2006
12
0.020
 Why?
Pleural Effusion, Malignant
1
2006
10
0.020
 Why?
Glucocorticoids
1
2010
574
0.020
 Why?
Hydrocephalus
1
1987
107
0.020
 Why?
Hyperthyroidism
1
2006
28
0.020
 Why?
Patient Isolation
1
2006
16
0.020
 Why?
Yttrium Radioisotopes
1
2006
52
0.020
 Why?
Ascites
1
2006
44
0.020
 Why?
DNA Damage
1
2008
384
0.020
 Why?
Lymphoma, Non-Hodgkin
1
2006
77
0.020
 Why?
Organophosphorus Compounds
1
2006
79
0.010
 Why?
Chromatography
1
1985
25
0.010
 Why?
Concanavalin A
1
1985
75
0.010
 Why?
ACTH Syndrome, Ectopic
1
1984
2
0.010
 Why?
Organometallic Compounds
1
2006
107
0.010
 Why?
Patient Education as Topic
1
2010
738
0.010
 Why?
Phosphates
1
2006
180
0.010
 Why?
Occipital Lobe
1
2004
24
0.010
 Why?
Biotransformation
1
1984
66
0.010
 Why?
Carbohydrate Metabolism
1
1984
62
0.010
 Why?
Brain Edema
1
2004
60
0.010
 Why?
Genomics
1
2009
715
0.010
 Why?
Recurrence
2
2000
1005
0.010
 Why?
Arginine Vasopressin
1
1984
42
0.010
 Why?
Thrombocytopenia
1
2006
186
0.010
 Why?
Vomiting
1
2004
126
0.010
 Why?
Corticotropin-Releasing Hormone
1
1984
61
0.010
 Why?
Oils
1
1983
21
0.010
 Why?
Bipolar Disorder
1
1985
235
0.010
 Why?
Motor Skills
1
2004
92
0.010
 Why?
Thyroid Neoplasms
1
2006
309
0.010
 Why?
Immunologic Factors
1
2003
231
0.010
 Why?
Antimetabolites, Antineoplastic
1
2001
91
0.010
 Why?
Pain
1
2006
785
0.010
 Why?
Opioid-Related Disorders
1
1987
484
0.010
 Why?
Psychometrics
1
2004
688
0.010
 Why?
Postoperative Period
1
2000
328
0.010
 Why?
Thorax
1
1999
41
0.010
 Why?
Michigan
1
1999
104
0.010
 Why?
Antibodies, Monoclonal
1
2006
1367
0.010
 Why?
Apoptosis
1
2008
2503
0.010
 Why?
Cysts
1
1999
108
0.010
 Why?
Bias
1
1999
196
0.010
 Why?
Meninges
1
1997
43
0.010
 Why?
Mercaptopurine
1
1996
15
0.010
 Why?
Mitomycin
1
1996
32
0.010
 Why?
Cross-Sectional Studies
1
2007
5061
0.010
 Why?
Biopsy
1
1999
1089
0.010
 Why?
Autoantibodies
1
1983
1466
0.010
 Why?
Decision Making
1
2001
849
0.010
 Why?
Cause of Death
1
1996
392
0.010
 Why?
Solutions
1
1993
151
0.010
 Why?
Neoplasms, Radiation-Induced
1
1993
71
0.010
 Why?
Cerebral Hemorrhage
1
1993
107
0.010
 Why?
Computer Simulation
1
1995
943
0.010
 Why?
Patient Compliance
1
1994
564
0.010
 Why?
Evaluation Studies as Topic
1
1989
170
0.000
 Why?
Double-Blind Method
1
1993
1876
0.000
 Why?
Melanocyte-Stimulating Hormones
1
1985
2
0.000
 Why?
Lithium
1
1985
37
0.000
 Why?
Postoperative Complications
1
1996
2479
0.000
 Why?
Brassica
1
1983
5
0.000
 Why?
Spain
1
1983
34
0.000
 Why?
Antigen-Antibody Complex
1
1983
84
0.000
 Why?
Drug Synergism
1
1984
371
0.000
 Why?
Syndrome
1
1983
339
0.000
 Why?
In Vitro Techniques
1
1984
1083
0.000
 Why?
Sheep
1
1984
837
0.000
 Why?
Animals
1
1984
35351
0.000
 Why?
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (490) concept(s)
_
Co-Authors Expand Description
See all (35) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)